ESMO 2022 | BladderPath: reducing bladder treatment times with MRI scans

Nicholas James, MBBS, PhD, FRCP, FRCR, The Royal Marsden NHS Foundation Trust, London, UK, gives an overview of the BladderPath study (ISRCTN35296862), which investigates the feasibility and efficacy of MRI scans to diagnose bladder cancer. Overall, MRI scans reduced the time to treatment by an average of 30 days and was feasible within the NHS. It additionally enabled more accurate and expedited identification of patients who will benefit from trans urethral resection of bladder tumour (TURBT). Prof. James also highlights the potential use of liquid biopsies with the analysis of tumor DNA in urine. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.